Cite

HARVARD Citation

    Clément‐Zhao, A. et al. (2018). Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer. BJU international. pp. 203-208. [Online]. 
  
Back to record